ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO1102

Validation of the Novel SOMAscan-Based Proteomic Platform in ESRD

Session Information

Category: Pathology and Lab Medicine

  • 1502 Pathology and Lab Medicine: Clinical


  • Han, Zhongji, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Xiao, Zhousheng, The University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Quarles, Leigh Darryl, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

End stage renal disease (ESRD) is characterized by complex metabolic abnormalities. The clinical relevance of many abnormalities in ESRD remains unclear due to the lack of clinically applicable and reproducible diagnostic tests to measure the full spectrum of abnormal proteins and metabolites seen in these patients. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches in patients with ESRD. SOMAscan is a novel multiplex proteomic platform which can measure >1,300 circulating proteins, which, however, has not yet been validated in patients with ESRD. In the present study, we aimed to explore the reliability of SOMAscan for ESRD biomarker measurement.


We obtained plasma samples from 21 maintenance hemodialysis patients and applied the commercially available SOMAScan proteomic assay to simultaneously measure the concentrations of 1,372 proteins. We employed quality control assessments to remove the SOMAscan assay and sample bias and used Student’s t tests to identify differentially expressed SOMAmer reagents. We compared concentrations of SOMAScan-measured prostate specific antigen (PSA) between males and females to test for the presence of biologically expected differences. We validated the SOMAScan concentrations of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using ELISA. We used Pearson correlation coefficients for correlation analysis and we performed principal component analysis.


Patients were 57±14 years old, 52% were males and 48% were African American. All 21 samples passed the quality control assessments of SOMAscan assay. The mean (± standard deviation) SOMAScan PSA concentration was 4205.6 ± 2799.3 relative fluorescence units (RFU) in males vs. 1060.8 ± 1102.5 RFU in females (p<0.01), suggesting biological plausibility. Concentrations measured by SOMAscan correlated well with the ELISA results for FGF23 (R=0.970) and FGFR4 (R=0.507). No significant correlation was found between the FGFR1 SOMAscan and ELISA measurements (R=0.055).


There is a good albeit not perfect correlation between the SOMAscan assay and standard immunoassays. The SOMAscan technology may be useful for the measurement of circulating plasma proteins in ESRD.